In recent years, nivolumab plus platinum-based chemotherapy has demonstrated longer event-free survival for clinical stage IB-IIIA NSCLC without epidermal growth factor receptor gene mutation (EGFR) and anaplastic lymphoma kinase (ALK) translocation in CheckMate-816. This evidence concerns the gene ALK and non-small cell lung carcinoma.